PMID- 21692906
OWN - NLM
STAT- MEDLINE
DCOM- 20111026
LR  - 20110622
IS  - 1529-8027 (Electronic)
IS  - 1085-9489 (Linking)
VI  - 16
IP  - 2
DP  - 2011 Jun
TI  - A smooth transition protocol for patients with multifocal motor neuropathy going 
      from intravenous to subcutaneous immunoglobulin therapy: an open-label 
      proof-of-concept study.
PG  - 92-7
LID - 10.1111/j.1529-8027.2011.00330.x [doi]
AB  - Intravenous immunoglobulin (IVIG) is the first-line therapy for multifocal motor 
      neuropathy (MMN). This open-label multi-centre study (NCT00701662) assessed the 
      efficacy, safety, and convenience of subcutaneous immunoglobulin (SCIG) in 
      patients with MMN over 6 months, as an alternative to IVIG. Eight MMN patients 
      (42-66 years), on stable IVIG dosing, received weekly SCIG at doses equivalent to 
      previous IVIG using a "smooth transition protocol". Primary efficacy endpoint was 
      the change from baseline to week 24 in muscle strength. Disability, motor 
      function, and health-related quality of life (HRQL) endpoints were also assessed. 
      One patient deteriorated despite dose increase and was withdrawn. Muscle 
      strength, disability, motor function, and health status were unchanged in all 
      seven study completers who rated home treatment as extremely good. Four 
      experienced 18 adverse events, of which only two were moderate. This study 
      suggests that MMN patients with stable clinical course on regular IVIG can be 
      switched to SCIG at the same monthly dose without deterioration and with a 
      sustained overall improvement in HRQL.
CI  - (c) 2011 Peripheral Nerve Society.
FAU - Misbah, Siraj A
AU  - Misbah SA
AD  - Department of Clinical Immunology, John Radcliffe Hospital, Headington, Oxford, 
      UK. siraj.misbah@orh.nhs.uk
FAU - Baumann, Andreas
AU  - Baumann A
FAU - Fazio, Raffaella
AU  - Fazio R
FAU - Dacci, Patrizia
AU  - Dacci P
FAU - Schmidt, Dirk S
AU  - Schmidt DS
FAU - Burton, Janet
AU  - Burton J
FAU - Sturzenegger, Matthias
AU  - Sturzenegger M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Peripher Nerv Syst
JT  - Journal of the peripheral nervous system : JPNS
JID - 9704532
RN  - 0 (Immunoglobulins)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Demyelinating Diseases/*drug therapy
MH  - Disability Evaluation
MH  - Female
MH  - Humans
MH  - Immunoglobulins/*administration & dosage
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/*administration & dosage
MH  - Infusions, Subcutaneous
MH  - Male
MH  - Middle Aged
MH  - Muscle Strength/drug effects
MH  - Polyneuropathies/*drug therapy
MH  - Quality of Life
EDAT- 2011/06/23 06:00
MHDA- 2011/10/27 06:00
CRDT- 2011/06/23 06:00
PHST- 2011/06/23 06:00 [entrez]
PHST- 2011/06/23 06:00 [pubmed]
PHST- 2011/10/27 06:00 [medline]
AID - 10.1111/j.1529-8027.2011.00330.x [doi]
PST - ppublish
SO  - J Peripher Nerv Syst. 2011 Jun;16(2):92-7. doi: 10.1111/j.1529-8027.2011.00330.x.